Marion Leboyer, MD, PhD

  • 15Articles
  • 73.1KReads
  • 2001–2022Active
  • 114Collaborators
  • 901Citations

About

Marion Leboyer, MD, PhD, is affiliated with INSERM U955, Neuro-Psychiatrie Translationnelle, Université Paris-Est, and AP-HP, DMU IMPACT, Département Médical Universitaire de Psychiatrie, Hôpitaux Universitaires Henri Mondor, Créteil, France. With publications spanning from 2001 to 2022, Leboyer has contributed extensively to research on bipolar disorder, schizophrenia and schizoaffective disorders, mood disorders, depression, anxiety, suicide, anxiolytics, and metabolic disorders. The work includes studies on clinical characteristics, metabolic syndrome, cognitive function related to infections, and treatment adherence in these psychiatric conditions. Frequent collaborators include Chantal Henry, Bruno Etain, Ophélia Godin, Frank Bellivier, and David J. Kupfer.

Publications

JCP
Epilepsy and Suicide Attempt
Original Research

Epilepsy and Suicide Attempt

May 2, 2022

From a sample of 1,229 adults who attempted suicide, this study found an elevated frequency of epilepsy and identified clinical factors that might play a role.
, , , et al
JCP
Original Research

Metabolic Syndrome in Treatment-Resistant Depression

October 15, 2019

This study aimed to estimate the prevalence of metabolic syndrome and its components in patients with treatment-resistant depression and determine correlations with sociodemographic, clinical, and treatment-related factors—read the article...
, , , et al
JCP
Original Research

Metabolic Syndrome Predicts Relapse in Schizophrenia

September 18, 2018

Cardiovascular diseases are the primary cause of mortality in individuals with schizophrenia, yet no study has yet explored the impact of metabolic syndrome on schizophrenia relapse. This study explored...
, , , et al
JCP
Original Research

Effects of Herpesviridae and Toxoplasma gondii Infection on Cognition

January 25, 2017

Exposure to infectious agents has been proposed as a risk factor in the development of serious mental illness. How is cognitive functioning affected by these agents? Does exposure to...
, , , et al
JCP
Meta-Analysis

C-Reactive Protein Alterations in Bipolar Disorder: A Meta-Analysis

February 25, 2015

, , , et al
JCP
Article

Metabolic Syndrome in a French Cohort of Patients With Bipolar Disorder: Results From the FACE-BD Cohort

October 28, 2014

, , , et al
JCP
Original Research

Childhood Trauma Is Associated With Severe Clinical Characteristics of Bipolar Disorders

October 15, 2013

, , , et al
JCP
Review Article

Public and Nonprofit Funding for Research on Mental Disorders in France, the United Kingdom, and the United States

July 15, 2012

, , , et al
JCP
Original Research

Variables as Mediators or Moderators in Predicting Relapse to Any Type of Mood Episode in a Bipolar Maintenance Study

July 15, 2012

, , , et al
JCP
Original Research

Clinical Expression of Bipolar Disorder Type I as a Function of Age and Polarity at Onset: Convergent Findings in Samples From France and the United States

April 15, 2012

, , , et al
JCP
Original Research

Bipolar Disorder: New Perspectives in Health Care and Prevention

December 15, 2010

,
JCP
Original Research

Treatment Nonadherence and Neurocognitive Impairment in Bipolar Disorder

June 2, 2009

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe